PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payments of $30.0 million from Takeda Pharmaceutical Company Limited for database lock of the Hematide™/peginesatide Phase 3 clinical trials. Due to the recognition of revenue from these milestone payments, Affymax was profitable in the quarter ended June 30, 2010. The company continues to expect to incur substantial losses for the foreseeable future.
